New drug duo aims to slow advanced lung cancer

NCT ID NCT05215340

Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding the drug Dato-DXd to standard immunotherapy (pembrolizumab) helps people with advanced or metastatic non-small cell lung cancer live longer without their cancer growing. About 740 adults with a high level of a protein called PD-L1 will be randomly assigned to get the combo or pembrolizumab alone. The study compares how long it takes for the cancer to progress and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

740 people

The number who actually took part.

Started

Mar 2022

Expected to finish

Mar 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants eligible for inclusion in the study must meet all inclusion criteria within 28 days of randomization into the study. * Sign and date the Tissue Screening and Main Informed Consent Forms, prior to the start of any study-specific qualification procedures. * Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time of informed consent. * Histologically documented non-squamous NSCLC that meets all of the following criteria (Note: Subjects with squamous histology were eligible prior to Protocol Version 5.0. After Protocol Version 5.0, subjects with squamous histology are not eligible. Subjects with mixed histology, including those with a squamous component, remain eligible the study even after Protocol Version 5.0): 1. Stage IIIB or IIIC disease and not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC disease at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition). Participants with early-stage NSCLC who have relapsed should be restaged during screening to ensure their eligibility for the study. 2. Documented negative test results for epidermal growth factor receptor (EGFR), lymphoma kinase (ALK), and proto-oncogene1 (ROS1) actionable genomic alterations (AGAs) based on analysis of tumor tissue. If test results for EGFR, ALK, and ROS1 are not available, subjects are required to undergo testing performed locally for these genomic alterations. 3. No known AGAs in neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), rearranged during transfection (RET), mesenchymal-epithelial transition factor (MET), or other actionable driver kinases with locally approved therapies in the first-line setting. (Testing for genomic alterations besides EGFR, ALK, and ROS1 is not required prior to randomization). Subjects whose tumors harbor KRAS mutations are eligible for the study. * Has provided a formalin-fixed tumor tissue sample for the measurement of trophoblast cell surface protein 2 (TROP2) protein expression and for the assessment of other exploratory biomarkers. * Tumor has high programmed death receptor-1 (PD-L1) expression (TPS ≥50%) as determined by PD-L1 immunohistochemistry (IHC) 22C3 pharmDx assay by central testing (minimum of 6 slides). * Has an adequate treatment washout period before Cycle 1 Day 1. * Measurable disease based on local imaging assessment using RECIST Version 1.1. * Has left ventricular ejection fraction (LVEF) ≥50% by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before randomization. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at screening. * Has a life expectancy of at least 3 months. * Adequate bone marrow function within 7 days before randomization. Exclusion Criteria: * Has received prior systemic treatment for advanced or metastatic NSCLC. * Has received prior treatment for NSCLC with any of the following, including in the adjuvant/neoadjuvant setting: 1. Any agent, including an antibody-drug conjugate, containing a chemotherapeutic agent targeting topoisomerase I. 2. TROP2-targeted therapy. 3. Any anti-programmed death receptor-1 (PD-1), anti-PD-L1, or anti-PD-ligand 2 (L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137). 4. Any other immune checkpoint inhibitors. Participants who received adjuvant or neoadjuvant therapy OTHER than those listed above, are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced/metastatic disease. * Has spinal cord compression or active and untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases and who are asymptomatic may participate provided they are radiologically stable. * Has received prior radiotherapy \< 4 weeks of start of study intervention or more than 30 Gy (unit of ionizing radiation dose in the International System of Units) to the lung within 6 months of Cycle 1 Day 1. * History of another primary malignancy (beyond NSCLC) except for: 1. Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study treatment and of low potential risk for recurrence. 2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. 3. Adequately treated carcinoma in situ without evidence of disease. 4. Participants with a history of prostate cancer (tumor/node/metastasis stage) of Stage ≤T2cN0M0 without biochemical recurrence or progression and who in the opinion of the Investigator are not deemed to require active intervention. * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis including radiation pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Clinically severe pulmonary compromise, as judged by the investigator, resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement or prior complete pneumonectomy. * Uncontrolled or significant cardiovascular disease, including: 1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval \>470 ms regardless of sex (based on the average of the 12-lead electrocardiogram determination at screening). 2. Myocardial infarction within 6 months prior to randomization. 3. Uncontrolled angina pectoris within 6 months prior to randomization. 4. LVEF \<50% by ECHO or MUGA scan within 28 days before randomization. 5. New York Heart Association Class 2 to 4 congestive heart failure (CHF) at screening. 6. Uncontrolled hypertension (resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg) within 28 days before randomization. Participants with a history of Class 2 to 4 CHF prior to screening, must have returned to Class 1 CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible. * Clinically significant corneal disease. * Has received a live vaccine or live-attenuated vaccine (messenger ribonucleic acid and replication-incompetent adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first dose of study drug. For any participant receiving an approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine, please follow the vaccine label and/or local guidance. * Active, known, or suspected autoimmune disease (has an active autoimmune disease that has required systemic treatment in the past 2 years). * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosage \>10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy ≤7 days prior to the first dose of study drug. * Has known human immunodeficiency virus (HIV) infection that is not well controlled. * Has an active hepatitis or uncontrolled hepatitis B or active hepatitis C infection. * Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. * Had an allogeneic tissue/solid organ transplant. * Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients (including but not limited to polysorbate 80) of Dato-DXd or pembrolizumab.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic non-small cell lung cancer

Contacts and locations

Locations

A.O. Perugia Santa Maria della Misericordia

Perugia, 06132, Italy
AP-HP - Hopital Tenon

Paris, 75970, France
APHM - Hopital Nord

Marseille, 13015, France
AZ Nikolaas

Sint-Niklaas, 9100, Belgium
Adana Acibadem Hospital

Adana, 1130, Turkey (Türkiye)
Affiliated Cancer Hospital and Institute of Guangzhou Medical University

Guangzhou, 510095, China
Akdeniz University Hospital

Antalya, 7070, Turkey (Türkiye)
American Oncology Partners of Maryland

Bethesda, Maryland, 20817, United States
Amsterdam Umc, Location Vumc

Amsterdam, 1081 HZ, Netherlands
Aomori Prefectural Central Hospital

Aomori, Aomori, 030-8553, Japan
Arizona Oncology NAHOA

Irving, Texas, 75063, United States
Army Medical Center of PLA

Chongqing, 400042, China
Asan Medical Center

Songpa-gu, 5505, South Korea
Asst Sette Laghi Ospedale di Circolo e Fondazione Macchi

Varese, 21100, Italy
Astera Cancer Care

East Brunswick, New Jersey, 08816, United States
Austin Hospital

Heidelberg, Victoria, 3084, Australia
Az Maria Middelares - Campus Maria Middelares

Ghent, 9000, Belgium
Azienda Ospedaliera dei Colli

Naples, 80131, Italy
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Bioclinic Thessaloniki

Thessaloniki, 54622, Greece
Birmingham Heartlands Hospital

Birmingham, B9 5SS, United Kingdom
Bkmk Hospital

KecskemĂŠt, 6000, Hungary
Bordeaux University Hospital - Hopital Saint Andre

Bordeaux, 33075, France
CER SAN JUAN - Centro Polivalente de Asistencia e Investigación Clínica

San Juan, 5400, Argentina
CHU de Nantes

Nantes, 44093, France
CHU de Poitier Pole Regional de Cancerologie

Poitiers, 86000, France
CHUO

Ourense, 32005, Spain
Cancer Care Center of Brevard

Irving, Texas, 75063, United States
Cangzhou People's Hospital

Cangzhou, 610001, China
Centre Hospitalier Universitaire de Lille

Lille, 59000, France
Centre Hospitalier Universitaire de Montpellier

Montpellier, 34295, France
Centre Leon Berard

Lyon, 69008, France
Centro Clinico Champalimau

Lisbon, 1400-038, Portugal
Centro Hospitalar Universitário de São João

Porto, 4200-319, Portugal
Centro Hospitalar e Universitário do Porto

Porto, 4099-001, Portugal
Centro de Estudios Clínicos SAGA

Santiago, Santiago Metropolitan, 7500653, Chile
Centro de Estudos e Pesquisa de Hematologia e Oncologia - CEPHO

Santo André, 09060-870, Brazil
Centro de Investigacion Clinica de Oaxaca (CICLO)

Oaxaca City, 68020, Mexico
Centro de Investigaciones Clinicas Vina Del Mar

Viña del Mar, 254-0488, Chile
Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)

Buenos Aires, Argentina
Centro de Investigación Pergamino S. A.

Pergamino, 2700, Argentina
Centrul de Oncologie Sf Nectarie S.R.L.

Craiova, 200542, Romania
Chang Gung Memorial Hospital Cgmh - Kaohsiung Branch

Kaohsiung City, 833, Taiwan
Chang Gung Memorial Hospital LinKou

Taoyuan, 333, Taiwan
Chris Obrien Lifehouse

Camperdown, 2050, Australia
Chung Shan Medical University Hospital

Taichung, 40201, Taiwan
Chungbuk National University Hospital

Cheongju-si, North Chungcheong, 28644, South Korea
Clinica Viedma SA

Viedma, 8500, Argentina
Clínica de Neoplasias Litoral

Itajaí, 88301-220, Brazil
Cooperman Barnabas Medical Center

New Brunswick, New Jersey, 08901, United States
Cryptex Investigacion Clinica Sa de Cv

Cuauhtémoc, 06100, Mexico
DFCI - South Shore Hospital

South Weymouth, Massachusetts, 02190, United States
Dana Farber Cancer Institute - Foxborough

Foxborough, Massachusetts, 02035, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, 03766, United States
Dokkyo Medical University Hospital

Shimotsuga-gun, Tochigi, 321-0293, Japan
Dom Lekarski SA

Szczecin, West Pomeranian Voivodeship, 70-784, Poland
E-Da Hospital

Kaohsiung City, 824, Taiwan
Ege University

Bornova-İzmir, 35100, Turkey (Türkiye)
Evangelische Lungenklinik Berlin

Berlin, 13125, Germany
Faculty of Medicine Chulalongkorn University

Bangkok, 10330, Thailand
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz

Székesfehérvár, 8000, Hungary
Fudan University Shanghai Cancer Center

Shanghai Shi, 200032, China
Fundacion CENIT para la investigación en Neurociencias

Ciudad Autonoma de Buenos Aire, 1125, Argentina
Fundación Arturo Pérez López

Santiago, 7500921, Chile
Goztepe Prof. Dr. Suleyman Yalcin City Hospital

Istanbul, 34772, Turkey (Türkiye)
Grand Hopital de Charleroi - Hopital Saint Joseph

Charleroi, 6000, Belgium
Guangxi Medical University Affiliated Tumor Hospital

Nanning, Guangxi, 530021, China
Gyeongsang National University Hospital

Jinju, Gyeongsangnam-do, 52727, South Korea
Haikou People's Hospital

Haikou, 570208, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
Hopital FOCH

Suresnes, 92150, France
Hopital prive du Confluent

Nantes, 44277, France
Hospital CUF Porto

Porto, 4100-180, Portugal
Hospital Civil de Guadalajara Fray Antonio Alcalde

Guadalajara, 44280, Mexico
Hospital Clinic i Provincial de Barcelona

Barcelona, 08036, Spain
Hospital Clinico San Carlos

Madrid, 28040, Spain
Hospital Erasto Gaertner

Curitiba, 81520-060, Brazil
Hospital General Universitario Gregorio Marañon

Madrid, 28007, Spain
Hospital Privado de la Comunidad

Mar del Plata, B7602CBM, Argentina
Hospital Regional Universitario Malaga

Málaga, 29010, Spain
Hospital Universitari Vall D'Hebron

Barcelona, 8035, Spain
Hospital Universitari i Politècnic La Fe

Valencia, 46026, Spain
Hospital Universitario Arnau de Vilanova - Lleida

Lleida, 25198, Spain
Hospital Universitario Dr. Jose Eleuterio Gonzalez

Monterrey, 64460, Mexico
Hospital Universitario Fundacion Jimenez Diaz

Madrid, 28040, Spain
Hospital Universitario Miguel Servet

Zaragoza, 50009, Spain
Hospital Universitario Virgen Macarena

Seville, 41009, Spain
Hospital Universitario de Valme

Seville, 41014, Spain
Hubei Cancer Hospital

Wuhan, 430079, China
Hunan Cancer Hospital

Changsha, 410013, China
II Klinika Chorob Pluc I Gruzlicy

Bialystok, 15-450, Poland
IRCCS Istituto Oncologico Giovanni Paolo II

Bari, 70124, Italy
IRCCS Ospedale San Raffaele

Milan, 20132, Italy
Ifo Regina Elena

Rome, 144, Italy
Illinois Cancer Specialists

Irving, Texas, 75063, United States
Inner Mongolia Medical University- the Affiliated Hospital

Hohhot, 10050, China
Institut Bergonie

Bordeaux, 33076, France
Institut Paoli-Calmettes

Marseille, 13273, France
Instituto Nacional de Câncer - INCA

Rio de Janeiro, 20231-050, Brazil
Instituto Portuguas de Oncologia do Porto Francisco Gentil

Porto, 4200-072, Portugal
Instituto de Ensino e Pesquisas Sao Lucas

São Paulo, 01236-030, Brazil
Instituto de Oncología de Rosario

Rosario, S2000, Argentina
Instituto de Pesquisas em Saúde - IPS

Caxias do Sul, 95020-972, Brazil
Instituto do Cancer Brasil - Unidade Taubate

Taubaté, Brazil
Instytut Centrum Zdrowia Matki Polki

Lodz, Iodzkie, 93-338, Poland
Irccs Istituto Europeo Di Oncologia

Milan, 20141, Italy
Ironwood Cancer and Research Center

Chandler, Arizona, 85224, United States
Jeroen Bosch Ziekenhuis J BZ Hieronymus Bosch Hospital

's-Hertogenbosch, 5223 GZ, Netherlands
Jiamusi Tumor and Tuberculosis Hospital

Jiamusi, 154007, China
Jiangsu Province Hospital

Nanjing, 210029, China
Jilin Cancer Hospital

Changchun, Jilin, 130012, China
Johns Hopkins University

Baltimore, Maryland, 21205, United States
Juntendo University Hospital

Bunkyo-ku, Tokyo, 113-8431, Japan
Kanagawa Cancer Center

Yokohama, Kanagawa, 241-8515, Japan
Kanazawa University Hospital

Kanazawa, Ishikawa-ken, 920-8641, Japan
Kansai Medical University Hospital

Hirakata-shi, Osaka, 573-1191, Japan
Kantonsspital Baden

Baden, 5404, Switzerland
Kantonsspital Baselland

Liestal, A4410, Switzerland
Kantonsspital St. Gallen

Sankt Gallen, Switzerland
Karl-Landsteiner Institute for Lung Research and Pulmonary Oncology c/o Klinik Floridsdorf

Vienna, 1090, Austria
Klinikum Esslingen GmbH

Esslingen am Neckar, 73730, Germany
Klinikum Klagenfurt am Wörthersee Abteilung für Lungenkrankheiten

Klagenfurt, Austria
Klinikum der Universitaet Muenchen

München, 80336, Germany
Koo Foundation Sun Yat-Sen Cancer Center

Taipei, 112, Taiwan
Kurume University Hospital

Kurume-shi, Fukuoka, 830-0011, Japan
Kyungpook National University Chilgok Hospital

Daegu, 42119, South Korea
Kyushu University Hospital

Fukuoka, Fukuoka, 812-8582, Japan
Leiden University Medical Center

Leiden, 2333 ZA, Netherlands
Liaoning Cancer Hospital& Institute

Shenyang, 110801, China
Linyi Cancer Hospital

Linyi, 276000, China
LungenClinic Grosshansdorf

Großhansdorf, 22927, Germany
MS Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Sp. Jawna

Lublin, 20-064, Poland
Maryland Oncology Hematology

Irving, Texas, 75063, United States
Matsusaka Municipal Hospital

Matsusaka-shi, Mie-ken, 515-8544, Japan
McGill University Health Centre

Montreal, H4A 3J2, Canada
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Medical Park Seyhan Hospital

Seyhan /Adana, 1140, Turkey (Türkiye)
Memorial Ankara Hospital Ankara

Çankaya, 06520, Turkey (Türkiye)
Metropolitan Hospital

Neo Faliro, Athens, 14564, Greece
Metropolitan Hospital

Neo Faliro, 18547, Greece
Metropolitan Hospital

Piraeus, 18547, Greece
Montefiore Medical Center

The Bronx, New York, 10461, United States
NHO Iwakuni Clinical Center

Iwakuni-shi, Yamaguchi, 740-8510, Japan
NHO Kinki-Chuo Chest Medical Center

Sakai-shi, Osaka, 591-8555, Japan
NHO Shikoku Cancer Center

Matsuyama, Ehime, 791-0280, Japan
National Cancer Center

Goyang-si, 10408, South Korea
National Cancer Center Hospital East

Kashiwa-shi, Chiba, 277-8577, Japan
National Cheng Kung University Hospital Nckuh

Tainan, 704, Taiwan
National Hospital Organization Kyushu Cancer Center

Fukuoka, Fukuoka, 811-1395, Japan
National Taiwan University Hospital

Taipei, 100, Taiwan
Niigata Cancer Center Hospital

Niigata, Niigata, 961-8566, Japan
Nottingham University Hospitals

Nottingham, NG5 1PB, United Kingdom
Onco Clinic Consult SA

Craiova, 200094, Romania
Oncocenter-Oncologie Clinica SRL

Timișoara, 300166, Romania
Oncologico Potosino

San Luis Potosí City, 78209, Mexico
Oncosite - Centro de Pesquisa Clinica Oncologia

Ijuí, 98700-000, Brazil
Oncovida

Santiago, 7500000, Chile
Onze-Lieve-Vrouwziekenhuis Olvz - Campus Aalst

Aalst, 9300, Belgium
Orlandi Oncología

Santiago, 7501010, Chile
Osaka International Cancer Institute

Osaka, Osaka, 541-8567, Japan
Osaka Toneyama Medical Center

Osaka, 560-8552, Japan
Ospedale San Luca

Lucca, 55100, Italy
PIH Health Whittier Hospital

Whittier, California, 90602, United States
Peking University Cancer Hospital

Beijing, 100142, China
Peking University Peoples Hospital

Beijing, 100044, China
Peninsula and South Eastern Haematology and Oncology Group

Mount Waverley, Victoria, 3149, Australia
Policlinico Tor Vergata

Rome, 133, Italy
Prince of Songkla University PSU - Faculty of Medicine

Hat Yai, Changwat Songkhla, 90110, Thailand
Prince of Wales Hospital / The Chinese University of Hong Kong 99999

Hong Kong, 99999, Hong Kong
Providence Regional Cancer System

Lacey, Washington, 98503, United States
Pulmonology Hospital Torokbalint

Törökbálint, 2045, Hungary
Queen Elizabeth Hospital

Hong Kong, Hong Kong
Queen Mary Hospital

Pok Fu Lam, 999077, Hong Kong
Regional Cancer Care Associates LLC

Freehold, New Jersey, 07728, United States
Ridley-Tree Cancer Center

Santa Barbara, California, 93105, United States
Rijnstate Ziekenhuis

Arnhem, Gelderland, 6815 AD, Netherlands
SC Oncomed SRL

Timișoara, 300239, Romania
Sainte-Catherine Institut du Cancer Avignon-Provence (ICAP)

Avignon, 84000, France
Saiseikai Kumamoto Hospital

Kumamoto, Kumamoto, 861- 4193, Japan
Samsung Medical Center

Seoul, 6351, South Korea
Sanatorio Británico de Rosario

Rosario, S2002, Argentina
Sanatorio Parque

Rosario, S2001, Argentina
Santa Casa de Misericordia de Porto Alegre

Porto Alegre, 90050-170, Brazil
Sc Sigmedical Services Srl

Suceava, 720214, Romania
Semmelweis University Department of Pulmonology

Budapest, 1083, Hungary
Sendai Kousei Hospital

Sendai, Miyagi, 980-0873, Japan
Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea
Shanghai Pulmonary Hospital

Shanghai, 200433, China
Sichuan Cancer Hospital

Chengdu, Sichuan, 610049, China
Siriraj Hospital

Bangkok, 10700, Thailand
Sotiria General Hosptial of Chest Diseases

Athens, 11527, Greece
Southern Cancer Center

Irving, Texas, 75063, United States
Srinagarind Hospital

Muaeng, Changwat Khon Kaen, 40002, Thailand
St. Luke's Hospital

Thessaloniki, 55236, Greece
Szpitale Pomorskie Sp. z o.o.

Gdynia, Pomeranian Voivodeship, 81-519, Poland
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
Taipei Veterans General Hospital

Taipei, 11217, Taiwan
Teine Keijinkai Hospital

Sapporo, 006-8555, Japan
Texas Oncology - Northeast Texas

Irving, Texas, 75063, United States
Texas Oncology Gulf Coast

Irving, Texas, 75063, United States
Texas Oncology McAllen

Irving, Texas, 75063, United States
The Cancer Institute Hospital of JFCR

Kōtoku, Toyko, 135-8550, Japan
The Catholic Univ. of Korea, Seoul St. Mary'S Hospital

Seoul, 6591, South Korea
The First Affiliate Hospitalof Xi'An Jiaotong University

Xi'an, 710061, China
The First Affiliated Hospital Xiamen University

Xiamen, 361001, China
The First Affiliated Hospital of College of Medicine Zhejiang University

Hanghzou, 310003, China
The First Affiliated Hospital of Nanchang University

Nanchang, 330006, China
The First Hospital of China Medical University

Shenyang, 110001, China
The Oncology Institute of Hope and Innovation

Whittier, California, 90603, United States
The Queen Elizabeth Hospital

Woodville South, 5011, Australia
The Second People's Hospital of Neijiang

Neijiang, 641000, China
The Valley Hospital

Paramus, New Jersey, 07652, United States
Tianjin Medical University General Hospital

Tianjin, 300052, China
Toho University Omori Medical Center

Ōta-ku, Toyko, 143-8541, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

Bunkyō-Ku, Tokyo, 113-8677, Japan
UCLA HemOnc - Clinical Research Unit

Los Angeles, California, 90095, United States
UOC Oncologia

Chieti, 66100, Italy
UPCO - Unidade de Pesquisas Clínicas em Oncologia - Clinica Lacks

Pelotas, 96020-080, Brazil
Uch-Mhs D/B/A Memorial Health System

Colorado Springs, Colorado, 80909, United States
Union Hospital Affiliated With Tongji Medical College Huazhong University of Science and Technology

Wuhan, 430022, China
University Hospital Basel

Basel, 4031, Switzerland
University Hospital Kyoto Prefectural University of Medicine

Kyoto, 602-8566, Japan
University Hospital of Ioannina Uhi

Ioannina, 45500, Greece
University of Texas Health Science Center San Antonio

San Antonio, Texas, 78229, United States
Utah Cancer Specialists

Salt Lake City, Utah, 84106, United States
VA Puget Sound Health Care System - VAPSHCS

Seattle, Washington, 98108, United States
Veszprem Megyei Tudogyogyintezet Farkasgyepu

Farkasgyepű, 8582, Hungary
Xiangyang Central Hospital- 5 Lumen Avenue

Xiangyang, 441000, China
Xinjiang Tumor Hospital

Ürümqi, 830000, China
Yamaguchi-Ube Medical Center

Ube-shi, Yamaguchi, 755-0241, Japan
Yamanashi Prefectural Central Hospital

Kofu, Japan
Yunnan Cancer Hospital

Kunming, 650118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.